Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5454
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Segmentation of macular neovascularization and leakage in fluorescein angiography images in neovascular age-related macular degeneration using deep learning ; day:1 ; month:7 ; year:2022 ; pages:1-6
Eye ; (1.7.2022), 1-6
- Creator
-
Holomcik, David
Seeböck, Philipp
Gerendas, Bianca S.
Mylonas, Georgios
Najeeb, Bilal Haj
Schmidt-Erfurth, Ursula
Deak, Gabor
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-022-02156-6
- URN
-
urn:nbn:de:101:1-2022082119025920313453
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Holomcik, David
- Seeböck, Philipp
- Gerendas, Bianca S.
- Mylonas, Georgios
- Najeeb, Bilal Haj
- Schmidt-Erfurth, Ursula
- Deak, Gabor
- SpringerLink (Online service)
Other Objects (12)
Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
Correction to: Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Pipeline therapies for neovascular age related macular degeneration
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
Correction to: Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Pipeline therapies for neovascular age related macular degeneration
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment
Correction to: Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
Pipeline therapies for neovascular age related macular degeneration
Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)